ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis

This publication has 31 references indexed in Scilit:

• Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2009
• In SituProtein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy
  Cancer Investigation, 2009
• Non–Small Cell Lung Cancer Exhibits Transcript Overexpression of Genes Associated with Homologous Recombination and DNA Replication Pathways
  Cancer Research, 2009
• BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer
  PLOS ONE, 2007
• Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
  International Journal of Cancer, 2006
• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
  Annals of Oncology, 2006
• DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
  New England Journal of Medicine, 2006
• Suppression of Lung Tumor Formation by the Regulatory Subunit of Ribonucleotide Reductase
  Cancer Research, 2006
• An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines
  Cancer Research, 2004
• Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis
  Carcinogenesis: Integrative Cancer Research, 2000